The latest developments from suppliers of ingredients, development and manufacturing services, and related technologies for pharmaceutical and biopharmaceutical development and production.
Catalent Pharma Solutions reports on its supply pact with InterveXion, a Little Rock, Arkansas-headquartered clinical-stage biopharmaceutical company, to support the production of IXT-m200, InterveXion’s investigational anti-methamphetamine...
Cambrex, an East Rutherford, New Jersey-based contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), plans to begin a $5-million expansion of laboratory facilities at its site in Karlskoga, Sweden.
The company is...
Alcami, a contract development and manufacturing organization of active pharmaceutical ingredients (APIs) and drug products, has reached an agreement to be acquired by Madison Dearborn Partners, LLC (MDP), a Chicago-based private-equity firm. MDP...
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization of biologic-based drugs, has extended its gene therapy and viral vaccine fill / finish capabilities to provide services in support of late-phase candidates and...
Lonza has added hepatic stellate cells, Kupffer cells, and liver-derived endothelial cells to its hepatocytes portfolio for testing of in vitro drug models.
Lonza says hepatic non-parenchymal cells provide the building blocks to create more...
Recipharm, a Jordbro, Sweden-based contract development and manufacturing organization, has established a dedicated task force to manage the potential impact on its operations due to the UK’s withdrawal from the European Union (EU) (i.e.,...
The US Food and Drug Administration (FDA) has licensed a third monoclonal antibody drug substance to be manufactured at Samsung BioLogics’ biomanufacturing facility in Incheon, South Korea.
With this approval, the FDA has now approved...
WuXi Biologics, part of WuXi AppTec, a Shanghai, China-headquartered contract service provider, plans to invest 80 million Singapore dollars (US $60 million) to establish a biologics manufacturing facility in Singapore. It will be WuXi Biologics’...
Dipharma, a Baranzate, Italy-headquartered active pharmaceutical ingredients manufacturer, has completed its previously announced acquisition of Kalexsyn, a Kalamazoo, Michigan-headquartered contract research organization (CRO) providing chemistry...
West Analytical Services, part of West Pharmaceutical Services, is investing in new analytical capabilities to enable customers to pair new and more complex drug products with the right containment systems, delivery systems, and combination...
Catalent Pharma Solutions has completed the second phase of a $5.5-million expansion program at its Kansas City, Missouri facility to increase the controlled-substance and controlled-temperature storage capabilities for its clinical supply...
WuXi Biologics, part of WuXi AppTec, a contract service provider, has partnered with Bioasis Technologies, a Richmond, British Columbia, Canada-based biopharmaceutical company focused on drug-delivery across the brain–blood barrier, to develop and...
GE Healthcare Life Sciences is increasing the annual production capacity of its powdered cell-culture media by tenfold at its facility in Pasching, Austria. GE is also doubling its powdered cell-culture media manufacturing capacity in Logan, Utah...
WuXi Biologics, part of WuXi AppTec, a contract service provider, plans to build an integrated biologics development, clinical, and commercial manufacturing center in Shijiazhuang, Hebei province, North China.
The new biologics center will include...
Novasep, a Lyon, France-headquartered contract manufacturer and life-science service provider, has invested EUR 10 million ($11.8 million) in a commercial fill/finish facility for viral vectors, monoclonal antibodies (mAbs), and other low-volume...
